Eddie Reed

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Glenn J. Bubley, Michael A. Carducci, William L. Dahut et al. · Journal of Clinical Oncology · 1999 · 979 citations

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel

Olivier Rixe, Waldo Ortuzar, Manuel Álvarez et al. · Biochemical Pharmacology · 1996 · 612 citations

National Cancer Institute, Medicine, Pharmacology +7

Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways

Jing Fang, Chang Xia, Zongxian Cao et al. · The FASEB Journal · 2005 · 306 citations

Hif‐1 Expression, Immunology, Tumor Biology +18

Excision repair cross complementing-group 1: Gene expression and platinum resistance (Review) parameters in human breast cancer

Ramin Altaha, Xiaobing Liang, Jing Yu et al. · International Journal of Molecular Medicine · 2004 · 178 citations

Ercc1 Gene Expression, Platinum Resistance, Breast Oncology +15

The impact of disease severity on the informed consent process in clinical research

Monica H. Schaeffer, David S. Krantz, Alison Wichman et al. · The American Journal of Medicine · 1996 · 174 citations

Clinical Settings, Family Medicine, Medical Decision Making +11